Abstract
Aims: Thioredoxin-interacting protein (TXNIP) contributes to cellular redox-state homeostasis via binding and inhibiting thioredoxin (TRX). Increasing evidence suggests that cellular redox homeostasis regulates vascular endothelial growth factor (VEGF)-mediated signaling. This study aims to examine the redox-dependant role of TXNIP in regulating VEGF-mediated S-glutathionylation and angiogenic signaling. TXNIP-knockout mice (TKO) or wild-type (WT) treated with the reduced glutathione (GSH)-precursor, N-acetyl cysteine (WT-NAC, 500 mg/kg) were compared to WT using hypoxia-induced neovascularization model. Results: In response to hypoxia, retinas from TKO and WT-NAC mice showed significant decreases in reparative revascularization and pathological neovascularization with similar VEGF expression compared with WT. VEGF failed to stimulate vascular sprouting from aortic rings of TKO compared to WT mice. TKO mice or WT+NAC experienced reductive stress as indicated by twofold increase in TRX reductase activity and fourfold increase in reduced-GSH levels compared with WT. In human microvascular endothelial (HME) cells, VEGF stimulated co-precipitation between vascular endothelial growth factor receptor 2 (VEGFR2) with low molecular weight protein tyrosine phosphatase (LMW-PTP). Silencing TXNIP expression blunted VEGF-induced oxidation of GSH and S-glutathionylation of the LMW-PTP in HME cells. These effects were associated with impaired VEGFR2 phosphorylation that culminated in inhibiting cell migration and tube formation. Overexpression of TXNIP restored VEGFR2 phosphorylation and cell migration in TKO-endothelial cells. Innovation: TXNIP expression is required for VEGF-mediated VEGFR2 activation and angiogenic response in vivo and in vitro. TXNIP expression regulates VEGFR-2 phosphorylation via S-glutathionylation of LMW-PTP in endothelial cells. Conclusion: Our results provide novel mechanistic insight into modulating TXNIP expression as a potential therapeutic target in diseases characterized by aberrant angiogenesis. Antioxid. Redox Signal. 19, 2199–2212.
Introduction
Although physiological angiogenesis is important for wound healing and recovery after stroke and myocardial infarction, pathological angiogenesis is involved in atherosclerosis, tumor growth, and diabetic retinopathy (5, 11, 12, 24, 38). Vascular endothelial growth factor (VEGF) is one of the potent angiogenic growth factors that maintain endothelial cell survival and migration. VEGF-angiogenic signal occurs mainly via the activation of vascular endothelial growth factor receptor 2 (VEGFR2) also known as Flk-1 (22, 47, 48). Therefore, regulation of VEGFR2 activation is critical for the VEGF-mediated response. Over the past decade, evidence accumulated to emphasize the role of reactive oxygen species (ROS) as a signaling moiety for VEGF angiogenic signal (15, 20, 49). Yet, the role of antioxidants and their impact on modulating cellular redox homeostasis and angiogenic signal remain to be fully understood.
Innovation.
This study provides new insights into understanding the critical role of redox balance in regulating vascular endothelial growth factor (VEGF)-mediated angiogenic signal. In normal homeostasis, thioredoxin (TRX) system regulated by thioredoxin-interacting protein (TXNIP) counters the endogenously formed peroxynitrite to maintain VEGF receptor phosphorylation. Acute shift in redox balance genetically using TXNIP-knockout mice or high dose of N-acetyl cysteine impaired VEGF-mediated angiogenesis but not VEGF expression in vivo. We also illustrated that S-glutathionylation of the phosphatase low molecular weight protein tyrosine phosphatase (LMWPTP) as a possible mechanism by which silencing TXNIP expression impairs VEGFR2 phosphorylation in endothelial cells. These results highlight the importance of TXNIP as a potential target to control angiogenic response.
Endothelial cells have two major antioxidant systems, the glutaredoxin system and the thioredoxin (TRX) system. The crosstalk between the two systems, as indicated by the ratio of the oxidized to reduced glutathione (GSSG/GSH) reflects antioxidant capacity of the cell (18, 19). Shifting redox state to more GSSG reflects a state of oxidative stress, while shifting to more GSH reflects a state of reductive stress. A great body of evidence supports the emerging role of the TRX system in modulating VEGF and angiogenesis (17, 31, 33, 50). The TRX system is a ubiquitous thiol-reducing system that consists of TRX, NADPH, and homodimeric selenoprotein TRX reductase (36). TRXs are a family of proteins that have been identified in regulation of multiple biological processes in a cell-compartment specific fashion. TRX has two distinct isoforms; the cytosolic (TRX-1) and the more recently identified mitochondrial (TRX-2) isoform. The activity and expression of TRX is regulated by thioredoxin-interacting protein (TXNIP) that tightly control cellular redox state (41). TXNIP-knockout (TKO) mice have been previously characterized by marked increase in antioxidant defense compared to wild-type (WT) mice (28, 44). Upregulation of TXNIP expression has been reported under stress conditions including inflammation and hyperglycemia (7, 13, 42). Yet, whether TXNIP expression can play a role in modulating cellular redox state and VEGF-mediated angiogenesis remains unstudied.
Previous studies showed that VEGF-induced ROS targets protein tyrosine phosphatases (PTP) to regulate angiogenic signal (1, 30, 49). We have recently demonstrated that VEGF caused transient S-glutathionylation and oxidative inhibition of the low molecular weight PTP (LMW-PTP), a redox-regulated phosphatase that regulates cell adhesion and migration. While overexpression of LMW-PTP blunted VEGF-mediated angiogenic response (26), its inhibition enhanced VEGF-induced cell migration in endothelial cells (1). Yet, the redox-dependent role of TXNIP in regulating LMW-PTP and how it can modulate VEGF-mediated angiogenic response in vivo remain to be elucidated. The current studies utilized hypoxia-induced murine neovascularization model, a standard model for retinal angiogenesis (45). The model has two distinguished stages: initial stage of hyperoxia (75% oxygen) characterized with capillary dropout in the central retina, followed by a later stage of relative hypoxia (21% oxygen) characterized with retinal neovascularization including a physiological angiogenesis to fill the central retina and a pathological angiogenic response at the retina periphery. Using TKO or WT mice treated with high dose of the glutathione precursor NAC, we tested the hypothesis that shifting cellular redox state to reductive stress will scavenge VEGF-induced peroxynitrite and impair VEGFR2 phosphorylation and VEGF angiogenic signal by a mechanism involving the hyperactivation of LMW-PTP.
Results
Deficiency of TXNIP impairs reparative and pathological retinal neovascularization
TKO mice and WT mice were subjected to hypoxia-induced neovascularization model, a standard model of VEGF-mediated retinal angiogenesis in neonates (3, 45). In this model depicted in Supplementary Figure S1 (Supplementary Data are available online at www.liebertpub.com/ars), pups are exposed to initial high oxygen insult (p7–p12) followed by relative hypoxia at room air (p12–p17) that increases VEGF expression and drive physiological revascularization of the central retina (reparative angiogenesis) and pathological neovascularization that appears as tufts emerging from the mid-peripheral retinal capillaries (45). Retinas from TKO mice showed similar vascular density to WT at basal condition (Supplementary Figure S2). As shown in Figure 1, retinas from TKO showed impaired VEGF-mediated reparative and pathological angiogenesis compared with WT. TKO showed a reduction in physiological revascularization indicated by 2.6-fold increase in capillary-free area of the central retina (Fig. 1B, C) when compared to age-matched (p17) WT pups (Fig. 1A). TKO showed a 75% reduction in peripheral retinal neovascularization (Fig. 1E, F) when compared to age-matched (p17) WT pups (Fig. 1D).
Deficiency of TXNIP expression shifts redox state to reductive stress
We next evaluated expression of TXNIP and TRX-1 and antioxidant defense in response to hypoxia. In WT, hypoxia (p12–p14) induced TXNIP mRNA expression (2.2-fold) and protein expression (2.5-fold) compared with normoxia (Fig. 2A, B). TKO mice showed no TXNIP mRNA or protein expression under both normoxic and hypoxic conditions (Fig. 2A, B). A two-way ANOVA (2×2) analysis showed significant difference between hypoxia versus normoxia in both WT and TKO. In comparison with WT, retinas from TKO mice showed significant 1.7-fold increase in TRX mRNA and 1.6-fold increase in TRX-1 mRNA under normoxic (Fig. 2C). In WT, hypoxia (p12–p14) induced TRX mRNA expression (3-fold) and TRX-1 mRNA expression (4.25-fold) (Fig. 2C) and total TRX protein expression (1.6-fold) compared with normoxia (Fig. 2D). In TKO, hypoxia induced significant 2.2-fold increase in TRX and 2-fold in TRX-1 mRNA expression (Fig. 2C). Statistical analysis also showed a significant difference between WT versus TKO on TRX or TRX-1 expression. For protein levels, retinas from TKO showed 1.45-fold increase in TRX under normoxia and 1.8-fold under hypoxic condition. TKO were previously characterized by having significant increase in the ratio of NADH to NAD and the hepatic ratios of reduced to GSSG (28, 44). Under normoxic condition, TKO had significant 2-fold increases in retinal TRX reductase activity and 3.5-fold in plasma GSH when compared with age-matched p17 WT mice (Fig. 2E, F). Hypoxia is known to increase oxidative stress and consume antioxidant capacity. A two-way ANOVA (gene/Oxygen levels) revealed a significant difference between (WT vs. TKO) and (Normoxia vs. Hypoxia) on their interaction on TRX reductase activity and GSH levels. Exposure to hypoxia (p12–p17) caused 20% and 40% reduction in retinal TRX reductase activity in WT and TKO, respectively and 40% and 45% reduction in plasma GSH levels in WT and TKO, respectively (Fig. 2E, F).
Pharmacologically induced reductive stress impairs VEGF-induced neovascularization
We mimicked the acute shift in redox state observed in TKO by treating WT mice with a high dose (three times of the traditional antioxidant dose) of the thiol donor and GSH-precursor N-acetyl cysteine (NAC, 500 mg/kg, IP) during hypoxia from p12–p17. In comparison with WT (Fig. 3A, D), treatment with NAC (WT+NAC) decreased reparative angiogenesis indicated by 2.3-fold increase in central capillary-free area (Fig. 3B, C) and decreased pathological neovascularization by 70% at peripheral retina (Fig. 3E, F). Plasma of WT+NAC pups showed a fourfold increase in reduced-GSH levels when compared with age-matched p17 WT mice (Fig. 3G). We next evaluated the effect of TXNIP deficiency or high dose of NAC on peroxynitrite formation assessed by nitrotyrosine formation. As shown in Supplementary Figure S3, under normoxic condition, TKO mice showed 45% reduction in nitrotyrosine formation compared with WT. Hypoxia (p12–p14) induced 2.5-fold increase in the retinal nitrotyrosine formation in WT but not in TKO or WT+NAC.
Acute shift to reductive stress did not alter hypoxia inducible factor-1α or VEGF expression
TXNIP is a known target gene for hypoxia inducible factor 1α (HIF-1α), which is an essential transcriptional regulator for hypoxia-induced angiogenesis. Therefore, we examined the effect of hypoxia on retinal expression of HIF-1α and VEGF at p14, a time point for maximum VEGF expression in this model (8). Hypoxia (p12–p14) increased the expression of HIF-1α 2.2-fold in WT, 2.6-fold in TKO mice, and 2.1-fold in WT-NAC compared with corresponding normoxic controls (Fig. 4A). We next examined the impact of increased cellular antioxidant defense on VEGF mRNA and expression. A two-way ANOVA 2×2 analysis showed no significant interaction between WT versus TKO or WT-NAC. Statistical analysis showed a significant interaction between hypoxia versus normoxia in both WT and TKO. Hypoxia induced comparable increases in VEGF retinal mRNA (2.5-fold) in WT and (2.45-fold) in TKO mice and (2.55-fold) in WT-NAC compared with corresponding normoxic controls (Fig. 4B). Hypoxia also induced retinal VEGF protein expression (1.5-fold) in WT and (1.4-fold) in TKO mice (Fig. 4C) and (1.6-fold) in WT-NAC compared with corresponding normoxic controls (Fig. 4D).
Acute shift to reductive stress impairs retinal VEGFR2 activation in vivo
We next examined the auto-phosphorylation site (Y966), which is required for the VEGFR2 kinase activity. A two-way ANOVA was used to examine the effect of manipulation (WT vs. TKO or WT+NAC) and oxygen levels (Normoxia vs. Hypoxia) and revealed a significant interaction between WT versus TKO/WT+NAC on the phosphorylation of VEGFR2. Retinas from WT showed 1.8-fold increases in VEGFR2 phosphorylation in response to hypoxia. On the other hand, retinas from TKO mice showed a 60% reduction of VEGFR2 activation compared with WT under hypoxia and 35% reduction when compared with TKO under normoxia (Fig. 5A). In comparison to WT, retinas from WT+NAC showed significant 56% reduction in VEGFR2 phosphorylation under hypoxia (Fig. 5B) and 30% reduction under normoxia. To confirm our results, we examined the activation of Akt, a downstream target from VEGFR2. A 2×2 statistical analysis showed a significant difference between WT and TKO/WT+NAC in pAKT phosphorylation in normoxia and hypoxia. Hypoxia (p12–p14) stimulated Akt phosphorylation twofold in retinas from WT but not from TKO or WT+NAC (Fig. 5C).
VEGF stimulates protein–protein interaction between VEGFR2 and LMW-PTP
We and others have shown that LMW-PTP can modulate VEGF-mediated angiogenic response in endothelial cells (1, 26). We examined interaction of VEGFR2 with LMW-PTP, a redox-regulated phosphatase (14). Results show that VEGF stimulated protein–protein interaction of LMW-PTP with VEGFR2 evident by maximum co-precipitation after 15 min of VEGF stimulation in human microvascular endothelial (HME) cells (Fig. 6A). These results suggest that LMW-PTP regulates sustained rather than immediate VEGFR2 activation.
Silencing TXNIP expression blunts VEGF-mediated S-glutathionylation of LMW-PTP
We further investigated the molecular mechanism by which deficiency of TXNIP impairs VEGFR2 phosphorylation. TXNIP expression was successfully silenced in HME cells using siRNA as detailed in Supplementary Figure S4A. Silencing TXNIP expression caused a shift in cellular redox state toward more reductive milieu as indicated by 1.6-fold increase in GSH and 80% reduction of peroxynitrite formation assessed by nitrotyrosine formation in HME cells (Supplementary Fig. S4B, C). As shown in Figure 6B, VEGF caused a transient and significant decrease (∼40%) in reduced-GSH levels that was restored back to normal after 15 min in HME treated with scrambled siRNA. Silencing TXNIP with siRNA increased the cellular antioxidant buffer capacity so that it blunted the VEGF-mediated decreases in reduced-GSH levels. VEGF induced immediate receptor autophosphorylation as indicated by 1.8-fold increase in VEGFR2 activation in HME treated with scrambled siRNA but not in cells treated with TXNIP siRNA (Fig. 6C). S-glutathionylation is a reversible protective mechanism for cysteine modification in response to oxidative stress. We have recently shown that VEGF causes S-glutathionylation and inactivation of LMW-PTP that is reversible after 15–30 min (1). Indeed, VEGF caused S-glutathionylation of LMW-PTP that peaked at 5–10 min that went back to baseline by 30 min in HME treated with scrambled siRNA. Silencing TXNIP expression using siRNA blunted VEGF-mediated S-glutathionylation of LMW-PTP over 30 min of VEGF treatment (Fig. 6D).
Silencing TXNIP expression inhibits VEGF angiogenic response
VEGF-angiogenic properties were examined after silencing TXNIP in different assay models such as tube formation, cell migration, and aortic ring assay. As shown in Figure 7A, VEGF caused a 1.9-fold increase in the mean length of tube formation in HME cells treated with scrambled siRNA, but not in TXNIP siRNA. In parallel, VEGF caused a 1.6-fold increase in cell migration of HME treated with scrambled siRNA. Silencing TXNIP with siRNA impaired VEGF-mediated endothelial cells migration and did not show any significant difference from control microvascular endothelial cells (Fig. 7B). Inducing acute reductive stress using a high dose of NAC (10 mM), a five times higher than traditional antioxidant dose (2 mM) blunted VEGF-induced cell migration (Fig. 7C). Moreover, ex vivo studies using aortic rings of adult TKO mice showed 80% reduction in sprouting angiogenesis as indicated by length of tubes formed in Matrigel in response to VEGF when compared to WT (Fig. 7D).
TXNIP overexpression in TKO-endothelial cells restores VEGF angiogenic function
To demonstrate gain of VEGF angiogenic function in TKO-endothelial cells, we isolated and characterized microvascular endothelial cells from brains of TKO mice (Supplementary Fig. S5A). TXNIP was overexpressed using plasmid transduction via electroporation in TKO-endothelial cells (Supplementary Fig. S5B). Western blot analysis showed 10-fold increase in protein TXNIP expression (Fig. 8A). Transduction of TXNIP in TKO-endothelial cells restored VEGF-mediated VEGFR2 phosphorylation (1.4-fold) compared to TKO-endothelial cells (Fig. 8B). These effects coincided with twofold increase in VEGF-mediated cell migration in TKO cells expressing TXNIP (Fig. 8C).
Discussion
Our study demonstrated for the first time a novel redox-dependent mechanism of TXNIP in modulating VEGF-mediated angiogenic response in vivo and in vitro. Our results showed that TXNIP expression is required to achieve homeostasis of redox state and facilitate VEGF's angiogenesis in endothelial cells. Induction of reductive stress genetically using TKO mice or pharmacologically using high dose of NAC can blunt VEGF-mediated angiogenesis but did not alter VEGF levels. Our results demonstrate a critical role of S-glutathionylation of LMW-PTP as a novel regulatory mechanism for VEGFR2 activation and VEGF angiogenic function. Modulating TXNIP expression is a viable therapeutic target in diseases characterized by aberrant angiogenesis.
TXNIP is identical to vitamin D3 upregulated protein-1 (VDUP-1) and also is called thioredoxin-binding protein-2 (TBP-2). TXNIP belongs to the α-arrestin family so it may serve as adaptor and scaffold protein with several interacting domains to activate various signaling pathways [reviewed in Masutani et al. (34)]. TXNIP has been established to regulate the cellular redox state by binding to and inhibiting TRX. Although increasing evidence that cellular redox homeostasis can be an important regulator of angiogenesis (18), the role of TXNIP in mediating VEGF angiogenic signal is not fully understood. The present study documents the first in vivo evidence for redox-dependent mechanisms of TXNIP in modulating VEGF angiogenic signal rather than VEGF expression. Retinas from p12 TKO mice showed vascular density similar to WT at resting condition (Supplementary Fig. S2). Our results clearly demonstrate impaired VEGF-mediated angiogenic response observed in retinas from TKO or WT+NAC in vivo (Figs. 1 and 3), aortic rings from TKO (Fig. 7D) was not due to decreases in VEGF levels (Fig. 4), rather it can be attributed to disturbed cellular redox-state homeostasis. The current study highlights the importance of antioxidant dose for modulating VEGF angiogenic response. Administration of high dose of NAC (500 mg/kg) induced reductive stress, blunted both reparative and pathological angiogenesis. In contrast, we demonstrated that a standard dose of NAC (150 mg/kg) exerted vascular protective actions and promoted reparative angiogenesis in hypoxia-induced neovascularization (3). Similar to previous reports, our analyses (Fig. 2) demonstrated that TKO mice had no TXNIP mRNA expression or protein expression (27) and marked increases in antioxidant defense (28, 44). TKO and WT+NAC also showed significant reduction in peroxynitrite formation assessed by nitrotyrosine formation compared with WT under basal normoxic and hypoxic condition (Supplementary Fig. S3).
Changes in the intracellular GSSG/GSH ratio not only reflect redox state but can also alter angiogenic response by regulating expression of VEGF and stabilization of the redox-sensitive transcription factor HIF-1α (33, 46, 50). Of note, previous reports showed that the ratio of cytoplasmic Trx1 to TXNIP expression can be an important factor in redox-mediated regulation of angiogenesis (6, 43). Our results showed that hypoxia triggered expression of retinal total TRX and the TRX-1 (Fig. 2C) equally in WT and TKO and stabilized retinal HIF-1α levels and VEGF expression in WT, TKO, and WT+NAC (Fig. 4). These results suggest that HIF-1α is upstream of TRX protein expression as TXNIP deletion did not alter expression of total TRX or TRX-1 expression or stabilization of HIF-1α compared to WT. Prior studies pointed out that inhibiting TXNIP expression could impair VEGF expression independent to TRX binding (13, 21, 42). Other studies showed that enhanced TRX can increase VEGF expression (17, 19, 31, 50), which can account for the observation of similar VEGF levels in TKO and WT animals. These findings clearly suggest that impaired VEGF angiogenic response in this model is likely due to its impaired signaling rather than levels of VEGF. We have previously shown that peroxynitrite is required to sustain VEGFR2 activation in endothelial cells (20). Silencing TXNIP expression resulted in blunting VEGF-mediated peroxynitrite formation and shifting redox state to reductive stress and impaired VEGFR2 activation in HME (Figs. 6 and 7). Activation of VEGFR2 and its downstream target Akt was also impaired in retinas from TKO or WT+NAC (Figs. 5 and 6). Moreover, expression of TXNIP plasmid in TKO-endothelial cells restored VEGFR2 activation and angiogenic response (Fig. 8). Our results lend further support to recent reports showing that peroxiredoxin2 (29) or TXNIP expression (40) are essential for VEGFR2 activation and angiogenic response. The latter study demonstrated another redox-independent mechanism by which TXNIP is required for VEGFR2 internalization and activation. These results highlight the crucial and multiple roles by which TXNIP modulates VEGFR2 activation in endothelial cells. Future studies are warranted to explore similar roles in other tyrosine kinase receptors.
Negative regulation of VEGFR2 signaling by phosphatases is equally important for controlling angiogenic response. Several phosphatases have been identified to associate with and regulate VEGFR2 at different steps of angiogenesis including vascular endothelial PTP (35); SHP-1 (10); SHP2 (37); and LMW-PTP (26). The activity of LMW-PTP is tightly linked to redox changes and can be a molecular switch for regulation of the cell migration and the angiogenic process (14, 25). Our recent work showed that LMW-PTP activity is regulated by transient oxidation and S-glutathionylation resulting in its inactivation in response to VEGF (1). Previous studies showed a positive association between LMW-PTP and VEGFR2 (26, 39, 51). Herein, we confirmed the association between LMW-PTP and VEGFR2 in HME cells at 15 min, a time point where LMW-PTP activity is restored after a transient inactivation (1). Our results showed that knocking down TXNIP expression blunted VEGF-induced S-glutathionylation of LMW-PTP resulting in its hyperactivation and inhibition of VEGFR2. In support, LMW-PTP activity has been shown to be regulated by the glutathione reducing system and cellular redox state (9, 53). Although, recent report by Park et al. (2013) excluded the involvement of PTP1B or SHP1 in TXNIP-mediated regulation of VEGFR2 activation (40), future work is warranted to examine whether S-glutathionylation can play a role in modulating other phosphatases similar to LMW-PTP. In summary, the study provides mechanistic insight into modulating TXNIP expression as a potential therapeutic target in diseases characterized by aberrant angiogenesis. Our findings support a redox-dependent pathway by which TXNIP can modulate VEGFR2 angiogenic signal. We also identified blunting of the VEGF-induced S-glutathionylation of LMW-PTP as a molecular switch for angiogenesis.
Materials and Methods
Animals
Experiments were approved by the Institutional Committee for Animal Use in Research and Education at Charlie Norwood VA medical Center (ACORP # 04-12-043) and conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. All experiments were performed using age-matched WT mice C57Bl/6 mice (Jackson Laboratory, Bar Harbor, Maine) and TXNIP-knockout mice (TKO) that was provided as a kind gift from Dr. AJ Lusis and Dr. ST Hui at the BioSciences Center, San Diego State University (San Diego, CA). TKO mice have a global knockdown of the expression of functional TXNIP as characterized previously (27). TKO mice are similar in weight and activity to WT or heterozygous littermates, with no differences in food consumption or litter sizes.
TKO breeding and genotyping
Littermates of WT and homozygous TKO were used and genotyping was performed as described previously (27). Briefly, DNA was prepared by incubating ear tissue with proteinase K and digestion buffer for 1 h at 95°C. A mixture of primer sequence (5′-TGA-GGT-GGT-CTT-CAA-CGA-CC-3′. 5′-GGA-AAG-ACA-ACG-CCA-GAA-GG-3′ and 5′-CCT-TGA-GGA-AGC-TCG-AAG-CC-3′ [Integrated DNA Technnologies, Inc., San Diego, CA]), buffer and 2 mM MgCl2, and polymerase enzyme (GoTAG Hot start polymerase; Promega) were added to the DNA template. DNA segments were amplified using the Master plex-RealPlex2 (Eppendorf, Germany) and were detected with 1% agarose gel electrophoresis. Deleted TXNIP allele was detected at 530 bp while WT was detected at 699 bp.
Hypoxia-induced neovascularization
Hypoxia-induced neovascularization was induced in newborn mice as described previously (3, 16) and depicted in Supplementary Figure S1. On postnatal day 7 (p7), mice were placed along with their dam into a custom-built chamber (Biospherix, Redfield, NY) in which the partial pressure of oxygen was maintained at 70% for 5 days followed by 5 days in room air (relative hypoxia, 21%). One set of WT mice was treated during hypoxia (p12–p17) with the GSH precursor, NAC (500 mg/kg/day IP, from [p12–p17]; Sigma Chemical Co.). Pups were deeply anesthetized by IP injection of Avertin 240 mg/kg. One eye was enucleated and fixed in 2% paraformaldehyde overnight to be flat-mounted for vascular density. For the other eye, retinas were isolated and snap frozen for biochemical assays.
Analysis of physiological revascularization and pathological neovascularization
Retinal vascular density was analyzed using flat-mounted retinas labeled with biotinylated Griffonia simplicifolia lectin B4 and Texas Red–conjugated Avidin D (Vector Laboratories). Retinas were viewed and imaged with fluorescence AxioObserver Zeiss Microscope. The areas of retinal neovascularization were assessed on p17 as described previously (3). Results were expressed as percentage of the total retinal area. For comparing normal retinal vasculature at p12, flat-mounted retinas were imaged as shown in Supplementary Figure S2 and processed via FIJI software.
Cell culture
Primary cultures of HME cells from retina and supplies were purchased from Cell Systems Corporation. Experiments were performed using cells between passages (3–6). Cells were switched to serum-free medium 6 h prior to stimulation with VEGF 20 ng/ml (R&D).
Isolation of primary endothelial cells from TKO mice
Due to small tissue limitation of the retina, we elected to isolate microvascular endothelial cells from the brain. Isolation of endothelial cells was performed according to protocol by Wu et al. (52) with small modification. For each isolation six to ten mouse brains (at 0.3–0.5 g/mouse brain) were aseptically collected and rinsed in MCDB131 medium (Gibco BRL) supplemented with 2% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin, and 100 μg/ml streptomycin (Sigma Chemical Co.). Cerebral cortices devoid of cerebella, white matter, and leptomeninges were prepared by aseptic macroscopic dissection. The cortices were cut into small pieces. The brain pieces were digested in 15 ml 0.1% of collagenase/dispase (Boehringer Mannheim) supplemented with 2% FBS for 6 h at 37°C with occasional agitation. The digested microvessels were collected with centrifugation at 1000 g for 5 min. The pellet were suspended in 5 ml PBS and centrifuged at 20,000 g for 10 min at 4°C. The microvessels and individual endothelial cells located in the top layer were transferred to a new 14 ml tube and washed once with PBS. Twenty microliters of CD31 rat anti-mouse (BD Pharmingen, San Jose, CA) were added with gentle shaking for 3 h at 37°C. The microvessel pellets were centrifuged at 20,000 g for 10 min at 4°C and washed once. Fifty microliters of Dynabeads (sheep anti-rat I gG) (Invitrogen) were added to the microvessel and shaken for 35 min at room temperature. The beads were isolated using magnet, washed thrice with PBS, and then resuspended in 10 ml MCDB 131 complete medium supplemented with 30 μg/ml ECGS (Sigma Chemical Co.), 10% FBS, 15 U/ml heparin, 325 μg/ml glutathione, 1 μl/ml 2-mecaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin (all were obtained from Sigma Chemical Co.). The microvessel suspension was platted on rat tail collagen I (Roche Diagnostics) coated plastic ware and incubated at 37°C with 5% CO2 in air. The medium was changed after every 2 days. Final recovering is ∼1×106 P0 cells per gram of mouse brain tissue. Isolated cells were stained with the endothelial specific marker Isolectin-B4 as previously described for flat-mounted retinas (Supplementary Fig. S5A).
Silencing TXNIP expression
Transfection of HME cells was performed using Amaxa nucleofector and a kit for primary endothelial cells according to the manufacturer's protocol (Lonza). Optimization experiments that were performed showed that T005 program and 300 ng of TXNIP siRNA (Dharmacon) gave the maximum transfection efficacy for HME cells. Cells suspended in a nucleofection mixture with the siRNA and pmaxGFP were zapped and left in complete medium for 48 h to recover before experiments. Transfection efficiency was between 80%–90% as indicated by the number of GFP-expressing cells (data not shown) and western blots for TXNIP expression shown in Supplementary Figure S4A.
TXNIP overexpression
Overexpression of TXNIP in HME cells isolated from TKO mice was performed using Amaxa nucleofector and a kit for primary endothelial cells according to the manufacturer's protocol (Lonza). Optimization experiments that were performed showed that T005 program and 300 ng of TXNIP plasmid (Dharmacon) gave the maximum transfection efficacy for HME cells. Cells suspended in a nucleofection mixture with the plasmid and pmaxGFP were zapped and left in complete medium for 48 h to recover before experiments. Transfection efficiency was 85%–90% as indicated by the number of GFP-expressing cells (Supplementary Fig. S5B) and western blots for TXNIP expression (Fig. 8A).
Cell migration assay
Wound healing assay was performed as described before (20). Briefly, HME cells were grown to confluence and switched to serum-free medium 6 h prior to experiment. The monolayer was wounded with a single sterile cell scraper of fixed diameter. Images of wounded areas were taken immediately and after 18 h. Cell migration was calculated by measuring migration distance normalized to initial distance of wounding using AxioObserver Zeiss Microscope software and expressed as the percentage of untreated control cells.
Tube formation assay
Tube formation assay was performed using growth factor-reduced Matrigel (BD Biosciences) as described previously (32). HME were counted and plated at 2×104 cells/ml with Matrigel in a 96 well-plate. Eighteen hours later, images of the tube-like structures were captured and analyzed using Zeiss Axiovert microscope software.
Aortic ring assay
Eight-week-old adult males of WT and TKO mice were euthanized and the aortas were removed and immediately transferred to iced serum-free media. The periaortic fibroadipose tissue was carefully removed without damaging the aortic wall. The aorta was cut into one millimeter-long aortic segments. The aortic rings were then individually embedded in growth factor-reduced Matrigel for 10 days. Images of vascular sprouts were captured and analyzed using a Zeiss Axiovert microscope. The greatest distance from the aortic ring body to the end of the vascular sprouts was measured in three rings per animal, and each group contained three to four animals.
Oxidized and reduced glutathione
GSH was measured using the Northwest Life Science kit as described before (3). Briefly, reduced-GSH was calculated by subtracting the oxidized-GSSG from the total glutathione. For total glutathione, cells were lysed in phosphate buffer (100 mM potassium phosphate and 1 mM EDTA) and were mixed with an equal amount of DTNB (10 mM 5, 5′-dithiobis 2-nitrobenzoic acid (DTNB) in the presence of glutathione reductase and NADPH producing a yellow color measured at 412 nm. To detect GSSG, samples were treated with 10 mM 2-vinylpyridine (Sigma Chemical Co.) in ethanol to sequester all the reduced GSH then measured using the same protocol as the total glutathione.
TRX reductase activity
TRX reductase activity was performed using a colorimetric kit (Sigma Chemical Co.) as described previously (7). Briefly, retinal samples were homogenized in assay buffer followed by the addition of DTNB with NADPH. Reduction of DTNB produced a strong yellow color that was measured colorimetrically at 412 nm. TRX reductase activity was measured by the difference between DTNB measurement of sample and sample plus selective TRX reductase inhibitor and expressed as unit/μg/min. As the TRX reductase activity increases, the availability of free TRX increases. TXNIP is the endogenous inhibitor of the TRX and can affect the cellular redox state that will be reflected in TRX reductase activity.
Quantitative real-time PCR
The One-Step qRT-PCR kit (Invitrogen) was used to amplify 10 ng retinal mRNA and quantification was performed as described previously (7). PCR primers were designed to amplify TXNIP, TRX-1, and VEGF and were purchased from Integrated DNA Technnologies, Inc. TXNIP primers: forward 5′AAGCTGTCCTCAGTCAGAGGCAAT3′ and reverse primer 5′ATGACTTTCTTGGAGCCAGGGACA3′. Total TRX primers 5′GCCAAAATGGTGAAGCTGAT3′ and reverse primer 5′TGATCATTTTGCAAGGTCCA3′. VEGF primers were: forward 5′TGAGCCTTGTTCAGAGCGGAGAAA3′ and 5′TTCGTTTAACTCAAGCTGCCTCGC3′. TRX-1 primers were forward: 5′ATGGTGAAGCTGATCGAGAG3′ and reverse: 5′ TTAGGCATATTCAGTAATAGAGGCTTC3′. Amplification of 18S RNA (forward 5′CGCGGTTCTATTTTGTTGGT3′ and reverse 5′AGTCGGCATCGTTTATGGTC3′) was used as an internal control. Quantitative PCR was performed using a Realplex Master cycler. Expression of TXNIP, total TRX, VEGF, or TRX-1 was normalized to the 18S level and expressed as relative expression to control.
Immunoprecipitation and western blot analysis
Protein expression in isolated retinas or HME cells were analyzed as described previously (7). For VEGF, retinal lysates were subjected to heparin beads (Sigma Chemical Co.) as described before (23). The beads were pelleted at 5000 g for 1 min, washed in 400 mM NaCl and 20 mM Tris and loaded onto a 4%–20% gradient Trisglycine precast gel (BioRad). The primary antibodies were purchased as follows: VEGF (Rabbit polyclonal; Calbiocam), phospho-Akt (Rabbit polyclonal; Cell Signaling), or Akt (Rabbit polyclonal; Cell Signaling), LMW-PTP (Sheep; Exalpha), anti-GSH (Mouse monoclonal; Virogen), total TRX (Mouse monoclonal; Santa Cruz), and TXNIP (Rabbit polyclonal; Life Technology, Invitrogen). Primary antibodies were detected using a horseradish peroxidase-conjugated antibody and enhanced chemiluminescence (GE Healthcare).The films were scanned, and band intensity was quantified using densitometry software (Alpha Innotech). For S-glutathionylation immunoprecipitation, cell lysate (200 μg) was immunoprecipitated with LMW-PTP primary antibody (5 μg) and A/G agarose beads (Santa Cruz) overnight. The precipitated proteins were analyzed by SDS-PAGE and blotted with Anti-GSH and anti-LMW-PTP for loading.
Data analysis
All the results were expressed as mean±SE and the data were evaluated for normality and appropriate transformations were used when necessary. Figures 1, 3, 6, 8B, and Supplementary Figures S3 and S4 were evaluated by analysis of variance, and the significance of difference between groups was assessed by the post hoc test (Fisher's PLSD) and significance was defined as p<0.05. A two-way ANOVA was used to examine the effect of manipulation (WT vs. TKO or WT+NAC) and oxygen levels (Normoxia vs. Hypoxia) and their interaction on mRNA and expression of TXNIP, TRX-1; expression of HIF-1α, VEGF; nitrotyrosine levels; activation of Akt; GSH levels and TRXR activity. A two-way ANOVA was used to study the effect of manipulation (WT vs. TKO) and treatment (control vs. VEGF) and their interaction on tube formation, cell migration, and aortic ring assay. A Tukey's test was used to adjust for the multiple comparisons used to assess significant effects. NCSS 2007 was used for all analyses (NCSS, version 07.1.14 LLC; Kaysville). Statistical significance was determined at alpha=0.05.
Supplementary Material
Abbreviations Used
- FBS
fetal bovine serum
- GSH
reduced glutathione
- GSSG
oxidized glutathione
- HIF
hypoxia inducible factor
- HME
human microvascular endothelial
- LMW-PTP
low molecular weight protein tyrosine phosphatase
- NAC
N-acetyl cysteine
- ROS
reactive oxygen species
- TKO
TXNIP-knockout mice
- TRX
thioredoxin
- TXNIP
thioredoxin-interacting protein
- VEGF
vascular endothelial growth factor
- VEGFR2
vascular endothelial growth factor receptor 2
- WT
wild-type
Acknowledgments
Authors are grateful to Dr. A.J. Lusis for providing TKO mice. Source of research support: American Heart Association predoctoral fellowship award#10PRE3660004 to M.A.A., AHA Scientist Development Grant to A.B.E., and Career Development Award from Juvenile Diabetes Research Foundation (2-2008-149) to A.B.E. and R01-EY022408 to A.B.E.
Author Disclosure Statement
We do not have any commercial associations that might create a conflict of interest in connection with this article.
References
- 1.Abdelsaid MA. and El-Remessy AB. S-glutathionylation of LMW-PTP regulates VEGF-mediated FAK activation and endothelial cell migration. J Cell Sci 125: 4751–4760, 2012 [DOI] [PubMed] [Google Scholar]
- 2.This reference has been deleted.
- 3.Abdelsaid MA, Pillai BA, Matragoon S, Prakash R, Al-Shabrawey M, and El-Remessy AB. Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy. J Pharmacol Exp Ther 332: 125–134, 2010 [DOI] [PubMed] [Google Scholar]
- 4.This reference has been deleted.
- 5.Abo-Auda W. and Benza RL. Therapeutic angiogenesis: review of current concepts and future directions. J Heart Lung Transplant 22: 370–382, 2003 [DOI] [PubMed] [Google Scholar]
- 6.Adluri RS, Thirunavukkarasu M, Zhan L, Akita Y, Samuel SM, Otani H, Ho YS, Maulik G, and Maulik N. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. J Mol Cell Cardiol 50: 239–247, 2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Al-Gayyar MM, Abdelsaid MA, Matragoon S, Pillai BA, and El-Remessy AB. Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity. Br J Pharmacol 164: 170–180, 2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Al-Shabrawey M, Bartoli M, El-Remessy AB, Platt DH, Matragoon S, Behzadian MA, Caldwell RW, and Caldwell RB. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 167: 599–607, 2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Beauchamp MH, Sennlaub F, Speranza G, Gobeil F, Jr, Checchin D, Kermorvant-Duchemin E, Abran D, Hardy P, Lachapelle P, Varma DR, and Chemtob S. Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy. Free Radic Biol Med 37: 1885–1894, 2004 [DOI] [PubMed] [Google Scholar]
- 10.Bhattacharya R, Kwon J, Wang E, Mukherjee P, and Mukhopadhyay D. Src homology 2 (SH2) domain containing protein tyrosine phosphatase-1 (SHP-1) dephosphorylates VEGF Receptor-2 and attenuates endothelial DNA synthesis, but not migration*. J Mol Signal 3: 8, 2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Liou GI, and Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 6: 511–524, 2005 [DOI] [PubMed] [Google Scholar]
- 12.Carmeliet P. Angiogenesis in health and disease. Nat Med 9: 653–660, 2003 [DOI] [PubMed] [Google Scholar]
- 13.Cha-Molstad H, Saxena G, Chen J, and Shalev A. Glucose-stimulated expression of Txnip is mediated by carbohydrate response element-binding protein, p300, and histone H4 acetylation in pancreatic beta cells. J Biol Chem 284: 16898–16905, 2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Chiarugi P. PTPs versus PTKs: the redox side of the coin. Free Radic Res 39: 353–364, 2005 [DOI] [PubMed] [Google Scholar]
- 15.Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, and Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J Biol Chem 277: 3101–3108, 2002 [DOI] [PubMed] [Google Scholar]
- 16.Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, Sapieha P, Stahl A, Willett KL, and Smith LE. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 4: 1565–1573, 2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Dai S, He Y, Zhang H, Yu L, Wan T, Xu Z, Jones D, Chen H, and Min W. Endothelial-specific expression of mitochondrial thioredoxin promotes ischemia-mediated arteriogenesis and angiogenesis. Arterioscler Thromb Vasc Biol 29: 495–502, 2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Dunn LL, Buckle AM, Simpson P, Sieveking DP, Chow RW, Lim P, Ng and MKC Rescue of diabetes-related impairment of angiogenesis by gene silencing of thioredoxin-interacting protein. Circulation 120: S1142, 2010 [Google Scholar]
- 19.Dunn LL, Buckle AM, Cooke JP, and Ng MK. The emerging role of the thioredoxin system in angiogenesis. Arterioscler Thromb Vasc Biol 30: 2089–2098, 2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.El-Remessy AB, Al-Shabrawey M, Platt DH, Bartoli M, Behzadian MA, Ghaly N, Tsai N, Motamed K, and Caldwell RB. Peroxynitrite mediates VEGF's angiogenic signal and function via a nitration-independent mechanism in endothelial cells. Faseb J 21: 2528–2539, 2007 [DOI] [PubMed] [Google Scholar]
- 21.Farrell MR, Rogers LK, Liu Y, Welty SE, and Tipple TE. Thioredoxin-interacting protein inhibits hypoxia-inducible factor transcriptional activity. Free Radic Biol Med 49: 1361–1367, 2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29: 789–791, 2009 [DOI] [PubMed] [Google Scholar]
- 23.Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, and Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442, 1996 [DOI] [PubMed] [Google Scholar]
- 24.Folkman J. Angiogenesis. Annu Rev Med 57: 1–18, 2006 [DOI] [PubMed] [Google Scholar]
- 25.Giannoni E, Chiarugi P, Cozzi G, Magnelli L, Taddei ML, Fiaschi T, Buricchi F, Raugei G, and Ramponi G. Lymphocyte function-associated antigen-1-mediated T cell adhesion is impaired by low molecular weight phosphotyrosine phosphatase-dependent inhibition of FAK activity. J Biol Chem 278: 36763–36776, 2003 [DOI] [PubMed] [Google Scholar]
- 26.Huang L, Sankar S, Lin C, Kontos CD, Schroff AD, Cha EH, Feng SM, Li SF, Yu Z, Van Etten RL, Blanar MA, and Peters KG. HCPTPA, a protein tyrosine phosphatase that regulates vascular endothelial growth factor receptor-mediated signal transduction and biological activity. J Biol Chem 274: 38183–38188, 1999 [DOI] [PubMed] [Google Scholar]
- 27.Hui ST, Andres AM, Miller AK, Spann NJ, Potter DW, Post NM, Chen AZ, Sachithanantham S, Jung DY, Kim JK, and Davis RA. Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci U S A 105: 3921–3926, 2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Hui TY, Sheth SS, Diffley JM, Potter DW, Lusis AJ, Attie AD, and Davis RA. Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J Biol Chem 279: 24387–24393, 2004 [DOI] [PubMed] [Google Scholar]
- 29.Kang DH, Lee DJ, Lee KW, Park YS, Lee JY, Lee SH, Koh YJ, Koh GY, Choi C, Yu DY, Kim J, and Kang SW. Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell 44: 545–558, 2011 [DOI] [PubMed] [Google Scholar]
- 30.Kaplan N, Urao N, Furuta E, Kim SJ, Razvi M, Nakamura Y, McKinney RD, Poole LB, Fukai T, and Ushio-Fukai M. Localized cysteine sulfenic acid formation by vascular endothelial growth factor: role in endothelial cell migration and angiogenesis. Free Radic Res 45: 1124–1135, 2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kim WJ, Cho H, Lee SW, Kim YJ, and Kim KW. Antisense-thioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation. Int J Oncol 26: 1049–1052, 2005 [PubMed] [Google Scholar]
- 32.Kozak A, Ergul A, El-Remessy AB, Johnson MH, Machado LS, Elewa HF, Abdelsaid M, Wiley DC, and Fagan SC. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke 40: 1870–1876, 2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Langston W, Chidlow JH, Jr, Booth BA, Barlow SC, Lefer DJ, Patel RP, and Kevil CG. Regulation of endothelial glutathione by ICAM-1 governs VEGF-A-mediated eNOS activity and angiogenesis. Free Radic Biol Med 42: 720–729, 2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Masutani H, Yoshihara E, Masaki S, Chen Z, and Yodoi J. Thioredoxin binding protein (TBP)-2/Txnip and alpha-arrestin proteins in cancer and diabetes mellitus. J Clin Biochem Nutr 50: 23–34, 2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Mellberg S, Dimberg A, Bahram F, Hayashi M, Rennel E, Ameur A, Westholm JO, Larsson E, Lindahl P, Cross MJ, and Claesson-Welsh L. Transcriptional profiling reveals a critical role for tyrosine phosphatase VE-PTP in regulation of VEGFR2 activity and endothelial cell morphogenesis. FASEB J 23: 1490–1502, 2009 [DOI] [PubMed] [Google Scholar]
- 36.Meyer Y, Buchanan BB, Vignols F, and Reichheld JP. Thioredoxins and glutaredoxins: unifying elements in redox biology. Annu Rev Genet 43: 335–367, 2009 [DOI] [PubMed] [Google Scholar]
- 37.Mitola S, Brenchio B, Piccinini M, Tertoolen L, Zammataro L, Breier G, Rinaudo MT, den Hertog J, Arese M, and Bussolino F. Type I collagen limits VEGFR-2 signaling by a SHP2 protein-tyrosine phosphatase-dependent mechanism 1. Circ Res 98: 45–54, 2006 [DOI] [PubMed] [Google Scholar]
- 38.Munoz-Chapuli R, Quesada AR, and Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 61: 2224–2243, 2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Nicosia RF, Lin YJ, Hazelton D, and Qian X. Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am J Pathol 151: 1379–1386, 1997 [PMC free article] [PubMed] [Google Scholar]
- 40.Park Y, Park SY, Shi X, Pang J, Yan C, and Berk BC. Thioredoxin-interacting protein mediates sustained VEGFR2 signaling in endothelial cells required for angiogenesis. Arterioscler Thromb Vasc Biol 33: 737–743, 2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, and Lee RT. The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 281: 21884–21891, 2006 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Perrone L, Devi TS, Hosoya K, Terasaki T, and Singh LP. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 221: 262–272, 2009 [DOI] [PubMed] [Google Scholar]
- 43.Piao ZH, Yoon SR, Kim MS, Jeon JH, Lee SH, Kim TD, Lee HG, Bae KH, Min JK, Chung SJ, Kim M, Cho YS, Oh DB, Park SY, Chung JW, and Choi I. VDUP1 potentiates Ras-mediated angiogenesis via ROS production in endothelial cells. Cell Mol Biol (Noisy-le-grand) 55 Suppl: OL1096–OL1103, 2009 [PubMed] [Google Scholar]
- 44.Sheth SS, Castellani LW, Chari S, Wagg C, Thipphavong CK, Bodnar JS, Tontonoz P, Attie AD, Lopaschuk GD, and Lusis AJ. Thioredoxin-interacting protein deficiency disrupts the fasting-feeding metabolic transition. J Lipid Res 46: 123–134, 2005 [DOI] [PubMed] [Google Scholar]
- 45.Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, and D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101–111, 1994 [PubMed] [Google Scholar]
- 46.Tajima M, Kurashima Y, Sugiyama K, Ogura T, and Sakagami H. The redox state of glutathione regulates the hypoxic induction of HIF-1. Eur J Pharmacol 606: 45–49, 2009 [DOI] [PubMed] [Google Scholar]
- 47.Testa U, Pannitteri G, and Condorelli GL. Vascular endothelial growth factors in cardiovascular medicine. J Cardiovasc Med (Hagerstown) 9: 1190–1221, 2008 [DOI] [PubMed] [Google Scholar]
- 48.Uchida C. and Haas TL. Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle. Curr Pharm Des 15: 411–421, 2009 [DOI] [PubMed] [Google Scholar]
- 49.Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 71: 226–235, 2006 [DOI] [PubMed] [Google Scholar]
- 50.Welsh SJ, Bellamy WT, Briehl MM, and Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62: 5089–5095, 2002 [PubMed] [Google Scholar]
- 51.Wo YY, McCormack AL, Shabanowitz J, Hunt DF, Davis JP, Mitchell GL, and Van Etten RL. Sequencing, cloning, and expression of human red cell-type acid phosphatase, a cytoplasmic phosphotyrosyl protein phosphatase. J Biol Chem 267: 10856–10865, 1992 [PubMed] [Google Scholar]
- 52.Wu Z, Hofman FM, and Zlokovic BV. A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J Neurosci Methods 130: 53–63, 2003 [DOI] [PubMed] [Google Scholar]
- 53.Xing K, Raza A, Lofgren S, Fernando MR, Ho YS, and Lou MF. Low molecular weight protein tyrosine phosphatase (LMW-PTP) and its possible physiological functions of redox signaling in the eye lens. Biochim Biophys Acta 1774: 545–555, 2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.